OakChart

Fate Therapeutics Inc

FATEHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 9:41 AM ET

1.76-0.01 (-0.56%)
2026-11-11 15:43 CET
Market cap
215.18 USD m
Revenue, TTM
4.75 USD m
Net income, TTM
-124.43 USD m
Free cash flow, TTM
-106.97 USD m
EPS diluted, TTM
-1.03
P/E
-
Compare

Price

FATE against its 20, 50 and 200-day averages
2050200beat
1.502.002.503.007.7M15.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FATEclose 1.7620-day 1.9950-day 2.20200-day 1.991.76

45.5% under 3.23 on 13 Jul 2026. Last 15 sessions, 31.2% high to low

Profile

FATE
52-week range, 36% of the way up
0.953.23

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Employees161
IPOOct 01, 2013
Beta2.68
ATR, 14d0.15
Rel volume1.74
Short float8.60%
Insider own4.67%
Inst own57.45%

Snapshot

6 groups

Valuation

Index-
Market Cap213.96M
Enterprise Value149.32M
Income-124.43M
Sales4.75M
Book/sh1.09
Cash/sh1.14
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees161
IPOOct 01, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S45.05
P/B1.61
P/C1.54
P/FCF-
EV/EBITDA-
EV/Sales31.44
Quick Ratio4.41
Current Ratio4.41
Debt/Eq0.56
LT Debt/Eq0.52
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.03
EPS next Y-1.04
EPS next Q-0.26
EPS this Y11.13%
EPS next Y-1.76%
EPS next 5Y0.59%
EPS past 3/5Y26.67% 11.42%
Sales past 3/5Y-58.98% -26.71%
EPS Y/Y TTM21.90%
Sales Y/Y TTM-33.45%
EPS Q/Q8.41%
Sales Q/Q-100.00%
EarningsNov 05 BMO
EPS/Sales Surpr.7.44% -100.00%

Ownership

Insider Own4.67%
Insider Trans-2.47%
Inst Own57.45%
Inst Trans-1.78%
ROA-42.76%
ROE-67.79%
ROIC-61.47%
Gross Margin-140.82%
Oper. Margin-2760.04%
Profit Margin-2619.64%
SMA20-11.44%
SMA50-20.05%
SMA200-11.38%
Trades-

Technical

Shs Outstand121.53M
Shs Float115.90M
Short Float8.60%
Short Ratio6.95
Short Interest9.97M
52W High3.23 -45.51%
52W Low0.95 85.26%
Volatility9.26% 7.44%
ATR (14)0.15
RSI (14)35.27
Beta2.68
Rel Volume1.74
Avg Volume1.43M
Volume204,193

Performance

Perf Week-15.79%
Perf Month-12.00%
Perf Quarter-30.16%
Perf Half Y-17.56%
Perf YTD79.12%
Perf Year57.14%
Perf 3Y-14.56%
Perf 5Y-96.88%
Perf 10Y-39.93%
Recom2.09
Target Price5.56
Prev Close1.77
Price1.76
Change %-0.56%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
May 19, 2026ResumedJJefferiesBuy
Oct 31, 2025UpgradeHH.C. WainwrightNeutral → Buy$5+184.1%
Oct 27, 2025UpgradeWWedbushNeutral → Outperform$7+297.7%
Nov 18, 2024UpgradeBBofA SecuritiesUnderperform → Neutral
Jun 17, 2024UpgradePPiper SandlerNeutral → Overweight$4 → $6+240.9%
Mar 27, 2023ResumedWWells FargoEqual Weight$6+240.9%
Jan 24, 2023DowngradeHH.C. WainwrightBuy → Neutral$115 → $7+297.7%
Jan 06, 2023DowngradeWWedbushOutperform → Neutral$42 → $7+297.7%
Jan 06, 2023DowngradeTTruistBuy → Hold$46 → $7+297.7%
Jan 06, 2023DowngradeSStifelBuy → Hold$107 → $5.30+201.1%

Peers

Mkt cap
TickerCompanyMkt cap
IPSCCentury Therapeutics Inc305.21M
ALLOAllogene Therapeutics Inc319.20M
NKTXNkarta Inc97.45M
SANASana Biotechnology Inc725.11M
ARTVArtiva Biotherapeutics Inc201.80M
CABACabaletta Bio Inc309.77M
KYTXKyverna Therapeutics Inc316.32M
CRBUCaribou Biosciences Inc43.09M
CLLSCellectis ADR92.58M
ACETAdicet Bio Inc27.89M

Insider trading

latest 14 of 18
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Adawi KamalChief Financial OfficerNov 03 '26Sale2.056,58213,52593,418Nov 04 04:01 PM
Adawi KamalOfficerNov 03 '26Proposed Sale2.056,58213,525Nov 03 03:26 PM
TAHL CINDYSee RemarksAug 04 '26Sale2.4638,80095,405589,355Aug 05 04:03 PM
Valamehr BahramPresident and CEOAug 04 '26Sale2.4643,947108,101591,815Aug 05 04:01 PM
TAHL CINDYOfficerAug 04 '26Proposed Sale2.4638,80095,405Aug 04 04:40 PM
Valamehr BahramOfficerAug 04 '26Proposed Sale2.4643,947108,101Aug 04 04:34 PM
TAHL CINDYSee RemarksMay 20 '26Sale1.8825,59048,084628,155May 21 04:02 PM
Valamehr BahramPresident and CEOMay 20 '26Sale1.8828,94654,482635,762May 21 04:01 PM
Valamehr BahramOfficerMay 20 '26Proposed Sale1.8828,94654,482May 20 03:41 PM
TAHL CINDYOfficerMay 20 '26Proposed Sale1.8825,59048,084May 20 03:38 PM
TAHL CINDYSee RemarksMay 06 '26Option Exercise1.25166,664207,997653,745May 07 04:00 PM
EPSTEIN ROBERT SDirectorMay 05 '26Option Exercise1.6925,00042,25036,331May 06 04:01 PM
RASTETTER WILLIAM HDirectorMay 05 '26Option Exercise1.6925,00042,25036,331May 06 04:00 PM
TAHL CINDYSee RemarksJan 09 '26Sale1.0610,58911,275387,081Jan 12 04:04 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
DFMCU.S. Micro Cap Portfolio ETF Class Shares-
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B

News

latest 14 of 206
  • Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy (GlobeNewswire) -8.76%
  • Fate Therapeutics: Q3 Earnings Snapshot (Associated Press) -11.48%
  • Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
  • Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026 (GlobeNewswire)
  • Loading…
  • Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies (GlobeNewswire)
  • Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) (FinanceWire) -6.11%
  • Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences (GlobeNewswire)
  • Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN (GlobeNewswire)
  • Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 (GlobeNewswire)
  • Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting (GlobeNewswire)
  • Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.250-0.270-0.2500.001.149
2026Q22026-08-13-0.250-0.267-0.2512.081.3411
2026Q12026-05-13-0.260-0.280-0.2601.301.4911
2025Q42026-02-26-0.270-0.270-0.2721.371.3410
2025Q32025-11-13-0.270-0.292-0.2711.741.4412
2025Q22025-08-12-0.290-0.351-0.2871.910.8612
2025Q12025-05-13-0.320-0.383-0.3181.631.0712
2024Q42025-03-05-0.440-0.433-0.4431.861.3715
2024Q32024-11-12-0.400-0.417-0.4053.071.2418
2024Q22024-08-13-0.330-0.464-0.3276.771.3318
2024Q12024-05-09-0.470-0.472-0.4751.931.6618
2023Q42024-02-26-0.450-0.522-0.4471.681.5421
2023Q32023-11-08-0.460-0.560-0.4581.941.5523
2023Q22023-08-08-0.540-0.589-0.5360.935.4121
2023Q12023-05-03-0.190-0.623-0.19358.9834.4221
2022Q42023-02-28-0.580-0.862-0.58044.3617.8824

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.440-1.439-1.43910.689.67
2020FY-2.100-1.832-2.10531.4320.58
2021FY-2.240-2.208-2.23955.8550.85
2022FY-2.910-3.208-2.91096.3069.09
2023FY-1.640-1.718-1.63563.5363.40
2024FY-1.640-1.619-1.63813.6313.30
2025FY-1.150-1.145-1.1506.656.62
2026FY--1.022--5.71
2027FY--1.040--3.10
2028FY--1.130--3.09
2029FY--1.056--25.12
2030FY--0.792--105.26

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0911122.210.0015.00
2026Q4S2026-11-0611112.380.0015.00
2026Q4S2026-11-0510102.620.0015.00
2026Q4S2026-11-0210001.120.002.50
2026Q4S2026-10-2810101.120.002.50
2026Q4S2026-10-2710111.120.002.50
2026Q4S2026-10-1610221.120.002.50
2026Q4S2026-08-2911221.150.002.50
2026Q4S2026-08-2812221.200.002.50
2026Q4S2026-08-2311221.300.002.50
2026Q4S2026-08-1912221.200.002.50
2026Q4S2026-08-1412131.160.002.50
2026Q4S2026-08-1312221.410.005.00
2026Q4S2026-08-0412111.380.005.00

Estimate history

EPS, annual-1.02-1.185-1.439-2.105-2.239-2.91-1.635-1.638-1.148-1.0302
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.405-0.443-0.318-0.287-0.271-0.272-0.26-0.251-0.248
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual4.1064.7410.6831.43455.84696.363.53313.6316.6464.75
Period201720182019202020212022202320242025TTM
Sales, quarterly3.0741.861.6291.9071.7411.3691.2992.0820
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual52.64964.69475.7387.72295.72797.29598.627113.928115.36121.534
Period201720182019202020212022202320242025MRQ
Shares, quarterly113.885113.928114.604114.655115.337115.36116.273116.694121.534
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4.756.6513.6363.5396.3055.8531.4310.684.74
Cost of Goods Sold Incl. D&A11.4412.9018.9618.2813.765.85---
Gross Profit-6.69-6.25-5.3345.2582.5450.00---
Selling, General and Administrative Excl. Other124.41140.35190.21222.86390.93266.99156.43109.2170.63
Research and Development87.2994.03116.04143.41306.70209.67122.5485.5854.82
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-131.10-146.60-195.54-177.61-308.39-216.99-128.09-100.73-67.09
Interest Expense0.000.000.000.000.000.000.001.751.70
Unusual Expense0.380.8613.925.29-20.31-3.5347.700.000.00
Net Income Before Taxes-124.43-136.31-186.26-160.93-281.72-212.15-173.39-98.15-66.60
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-124.43-136.31-186.26-160.93-281.72-212.15-173.39-98.15-66.60
Net Income From Continuing Operations-124.43-136.31-186.26-160.93-281.72-212.15-173.39-98.15-66.60
Net Income-124.43-136.31-186.26-160.93-281.72-212.15-173.39-98.15-66.60
EPS (Recurring)-1.00-1.14-1.55-1.60-3.06-2.27-1.70-1.44-1.19
EPS (Basic, Before Extraordinaries)-1.03-1.15-1.64-1.64-2.91-2.24-2.10-1.44-1.19
EPS (Diluted)-1.03-1.15-1.64-1.64-2.91-2.24-2.10-1.44-1.19
EBITDA-119.66-133.70-176.58-159.33-294.63-211.14-125.00-98.53-65.89
Non-Operating Income (Expense)7.0511.1423.2021.976.361.312.404.332.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.6724.9241.5043.4678.7354.3630.7517.416.29
Price To Sales Ratio61.7017.5613.765.7910.1599.27238.32124.95152.11
Gross Margin-140.82-94.12-39.1171.2285.7189.52---
Operating Margin-2,760.04-2,205.90-1,434.52-279.56-320.23-388.56-407.47-943.14-1,415.44
Net Margin-2,619.64-2,051.08-1,366.46-253.30-292.55-379.89-551.59-919.00-1,405.02
Shares Outstanding121.53115.36113.9398.6397.2995.7387.7275.7364.69
Market Capitalization215.18215.18187.93368.77980.455,587.287,933.101,479.36827.78

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.002.081.301.371.741.911.631.86
Cost of Goods Sold Incl. D&A2.682.782.923.063.233.283.334.81
Gross Profit-2.68-0.70-1.62-1.69-1.49-1.37-1.70-2.95
Selling, General and Administrative Excl. Other29.5730.4431.3833.0333.2535.6039.5844.06
Research and Development21.5421.6121.7922.3622.6124.1525.8028.80
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-32.25-31.13-33.00-34.72-34.73-36.97-41.28-47.01
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.150.580.08-0.130.090.07-0.2814.07
Net Income Before Taxes-30.69-30.16-31.21-32.37-32.25-34.07-37.62-52.15
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-30.69-30.16-31.21-32.37-32.25-34.07-37.62-52.15
Net Income From Continuing Operations-30.69-30.16-31.21-32.37-32.25-34.07-37.62-52.15
Net Income-30.69-30.16-31.21-32.37-32.25-34.07-37.62-52.15
EPS (Recurring)-0.25-0.25-0.26-0.27-0.27-0.29-0.32-0.36
EPS (Basic, Before Extraordinaries)-0.25-0.25-0.26-0.27-0.27-0.29-0.32-0.44
EPS (Diluted)-0.25-0.25-0.26-0.27-0.27-0.29-0.32-0.44
EBITDA-29.57-28.35-30.08-31.66-31.51-33.69-37.95-42.20
Non-Operating Income (Expense)1.411.551.872.222.582.973.388.93
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.703.523.935.534.867.157.389.12
Price To Sales Ratio61.7050.0822.8117.6321.0115.677.0114.26
Gross Margin--33.53-124.63-123.74-85.35-71.89-104.60-158.76
Operating Margin--1,495.39-2,540.42-2,536.23-1,995.12-1,938.54-2,534.07-2,527.47
Net Margin--1,448.56-2,402.85-2,364.79-1,852.38-1,786.58-2,309.45-2,803.92
Shares Outstanding121.53116.69116.27115.36115.34114.66114.60113.93
Market Capitalization215.18314.71139.52113.34145.32128.3990.54187.93

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments203.66279.07315.18436.23615.91482.92221.43201.01100.95
Short Term Receivables1.625.642.7338.488.685.510.000.500.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.437.2013.6427.378.835.895.663.691.65
Total Current Assets208.70291.91331.54502.07633.41494.32227.09205.20102.60
Net Property, Plant & Equipment98.53110.89158.51176.09162.2599.3934.175.122.55
Total Investments and Advances11.7037.8816.1620.17115.8915.2339.670.230.12
Long-Term Note Receivable--0.007.209.8713.511.341.96-
Intangible Assets0.00--------
Other Assets0.000.010.010.030.030.010.010.530.02
Total Assets318.94440.69506.22705.56921.46622.46302.27213.03105.29
Short Term Debt Incl. Current Port. of LT Debt4.567.426.185.635.583.351.692.440.00
Accounts Payable2.669.374.728.278.616.285.824.211.68
Other Current Liabilities28.8521.7428.20100.1667.0975.9320.2920.629.37
Total Current Liabilities36.0738.5239.09114.0581.2885.5627.8127.2611.05
Long Term Debt73.2977.8597.36103.71109.2493.9425.2312.4514.81
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities2.405.601.353.8652.0958.514.4812.852.25
Total Liabilities111.75121.97137.80221.62242.62238.0157.5252.5628.10
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity207.18318.72368.41483.94678.84384.44244.75160.4777.19
Total Shareholders Equity207.18318.73368.42483.94678.84384.44244.76160.4777.19
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity207.18318.73368.42483.94678.84384.44244.76160.4777.19
Total Liabilities & Stockholders Equity318.94440.69506.22705.56921.46622.46302.27213.03105.29
Book Value Per Share1.802.803.744.977.094.383.232.481.47
Tangible Book Value Per Share1.802.803.744.977.094.383.232.481.47
Full-Time Employees16118118155144927917810480
Price to Book Ratio1.620.520.921.898.2520.756.065.175.54
Return on Assets-35.89-39.34-26.56-34.63-27.48-37.50-38.09-41.84-42.88
Return on Equity-51.84-54.21-37.76-48.46-39.90-55.11-48.44-56.05-57.14
Return on Invested Capital-48.60-46.97-34.55-47.94-26.92-36.24-36.35-38.51-46.69
Quick Ratio5.797.588.484.407.795.788.177.539.29
Current Ratio5.797.588.484.407.795.788.177.539.29

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-124.43-136.31-186.26-160.93-281.72-212.15-173.39-98.15-66.60
Depreciation11.4412.9018.9618.2813.765.853.092.191.20
Other Funds (Non Cash)12.9621.0746.38-8.8054.4741.33143.849.1425.00
Funds from Operations-100.04-102.34-120.92-151.44-213.50-164.97-26.46-86.81-40.39
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.43-3.74-1.9619.18-34.712.10-12.773.641.74
Cash from Operating Activities-105.46-106.08-122.87-132.26-248.21-162.87-39.23-83.17-38.65
Capital Expenditures-1.51-5.95-0.73-6.15-35.57-50.70-4.93-7.39-2.30
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.240.360.000.000.000.000.000.000.00
Purchase or Sale of Investments93.88116.7612.95118.82202.32-273.32-156.14-150.061.84
Purchase of Investments-142.47-195.14-317.75-358.81-404.80-968.16-277.34-248.86-55.66
Sale Or Maturity of Investments236.35311.90330.70477.63607.11694.84121.2098.8057.50
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities92.61111.1712.22112.67166.75-324.02-161.08-157.45-0.46
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock8.030.0094.820.099.21453.13282.35164.93137.27
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock8.030.0094.820.099.21453.13282.35164.93137.27
Proceedsfrom Stock Options7.600.0094.530.090.00411.74272.69162.41137.27
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-15.000.00
Change in Long Term Debt0.000.000.000.000.000.000.00-15.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-15.000.00
Net Financing Active Other Cash Flow3.015.495.070.000.000.000.490.003.51
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities11.055.4999.890.099.21453.13282.84149.93140.78
Net Change in Cash-1.8110.57-10.76-19.51-72.25-33.7682.53-90.70101.67
Free Cash Flow-106.97-112.04-123.60-138.42-283.77-213.57-44.16-90.57-40.95
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments139.13153.77174.82203.66215.42222.83
Short Term Receivables0.881.001.501.622.083.40
Inventories0.000.000.000.000.000.00
Other Current Assets4.253.183.203.433.754.17
Total Current Assets144.26157.95179.53208.70221.25230.40
Net Property, Plant & Equipment88.9292.1095.3498.53101.89104.91
Total Investments and Advances5.1010.0510.0511.7020.5336.32
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets238.28260.10284.92318.94343.67371.63
Short Term Debt Incl. Current Port. of LT Debt5.114.924.744.564.755.66
Accounts Payable2.923.263.282.663.504.04
Other Current Liabilities24.6624.4122.6728.8519.8618.98
Total Current Liabilities32.6932.5930.6936.0728.1128.67
Long Term Debt69.3870.7572.0573.2974.4975.67
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities3.173.322.482.407.005.92
Total Liabilities105.24106.67105.21111.75109.61110.27
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity133.03153.44179.70207.18234.06261.36
Total Shareholders Equity133.03153.44179.71207.18234.07261.36
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity133.03153.44179.71207.18234.07261.36
Total Liabilities & Stockholders Equity238.28260.10284.92318.94343.67371.63
Book Value Per Share1.091.311.551.802.032.28
Tangible Book Value Per Share1.091.311.551.802.032.28
Full-Time Employees---161--
Price to Book Ratio1.621.750.670.480.550.45
Return on Assets-42.76-39.89-38.01-35.89-37.23-38.10
Return on Equity-67.79-60.75-55.50-51.84-52.35-52.11
Return on Invested Capital-15.16-13.45-12.40-11.54-10.45-10.11
Quick Ratio4.414.855.855.797.878.04
Current Ratio4.414.855.855.797.878.04

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-30.69-30.16-31.21-32.37-32.25-34.07
Depreciation2.682.782.923.063.233.28
Other Funds (Non Cash)1.832.753.444.944.146.13
Funds from Operations-26.18-24.63-24.86-24.37-24.88-24.66
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.711.19-5.961.050.500.07
Cash from Operating Activities-27.89-23.43-30.82-23.31-24.37-24.59
Capital Expenditures0.00-0.08-0.24-1.19-2.20-1.36
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.240.000.12
Purchase or Sale of Investments26.8414.6423.8328.5923.4720.83
Purchase of Investments-17.66-58.35-28.73-37.73-57.98-50.81
Sale Or Maturity of Investments44.5072.9852.5566.3281.4571.64
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities26.8414.5623.5927.6321.2719.59
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock7.620.410.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock7.620.410.000.000.000.00
Proceedsfrom Stock Options7.600.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.001.320.001.692.481.32
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities7.621.740.001.692.481.32
Net Change in Cash6.56-7.14-7.246.01-0.63-3.67
Free Cash Flow-27.89-23.51-31.06-24.51-26.58-25.95

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 13.63M 2025: 6.65M
United States2024: 13.63M 2025: 6.65M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.60%10.0M115.9M1.58M
2026-10-159.30%10.6M114.2M1.66M
2026-09-309.42%10.8M114.2M2.06M
2026-09-158.22%9.4M114.2M2.70M
2026-08-317.98%9.1M114.2M3.14M
2026-08-147.46%8.5M114.1M3.71M
2026-07-316.95%7.7M110.6M4.13M
2026-07-156.62%7.3M110.6M4.06M
2026-06-306.72%7.4M110.6M3.63M
2026-06-159.79%10.8M110.6M2.88M
2026-05-299.68%10.7M110.5M2.52M
2026-05-158.80%9.7M110.5M2.06M
2026-04-309.32%10.3M110.1M1.46M
2026-04-159.33%10.3M110.1M1.62M
2026-03-318.95%9.9M110.1M1.67M
2026-03-138.46%9.3M110.1M1.67M
2026-02-278.69%9.6M110.1M1.62M
2026-02-1310.19%11.1M109.2M1.51M
2026-01-3010.44%11.4M109.2M1.58M
2026-01-1510.47%11.4M109.2M1.63M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.001.30-2140.00---
call1.000.000.001.06-3600.00---
call1.500.000.000.75-1840.00---
call2.000.000.000.20-7570.00---
call3.000.000.000.01-1,5780.00---
call4.000.000.000.05-3540.00---
call5.000.000.000.07-5460.00---
call6.000.000.000.03-95.000.00---
put0.500.000.000.04-8.000.00---
put1.000.000.000.15-5.000.00---
put1.500.000.000.02-84.000.00---
put2.000.000.000.35-1640.00---
put3.000.000.000.90-1280.00---
put4.000.000.001.65-3590.00---
put5.000.000.002.80-51.000.00---
put6.000.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09SCHEDULE 13D/ASEC
2026-11-05S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-11-05424B5SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-09-288-KCurrent report2026-09-25SEC
2026-08-13S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-04SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-153Initial statement of beneficial ownership of securities2026-06-12SEC
2026-06-158-KCurrent report2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-048-KCurrent report2026-06-04SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110013.52K1
2026-100000
2026-090000
2026-0800203.51K2
2026-070000
2026-060000
2026-0500102.57K2
2026-040000
2026-030000
2026-020000
2026-010016.83K2
2025-120000
2025-110000

Institutional holders

Manager% owned
Redmile Group, LLC11.04%
BlackRock, Inc.6.26%
ACADIAN ASSET MANAGEMENT LLC3.98%
VANGUARD PORTFOLIO MANAGEMENT LLC3.90%
VANGUARD CAPITAL MANAGEMENT LLC3.81%
AQR CAPITAL MANAGEMENT LLC3.29%
TWO SIGMA INVESTMENTS, LP3.08%
JOHNSON & JOHNSON2.82%
RENAISSANCE TECHNOLOGIES LLC2.56%
MILLENNIUM MANAGEMENT LLC2.09%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.74%
VANGUARD STRATEGIC EQUITY FUND2.54%
BlackRock Advantage Small Cap Core Fund1.31%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
Fidelity Small Cap Index Fund0.93%
BRUCE FUND0.85%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.68%
T. Rowe Price Small-Cap Value Fund, Inc.0.54%
VANGUARD RUSSELL 2000 INDEX FUND0.48%
Fidelity Extended Market Index Fund0.43%

OakChart. FATE. Cached 15 minutes.